INFLUENCE OF TOCILIZUMAB ON THE OUTCOME OF PATIENTS WITH COVID-19. RETROSPECTIVE OBSERVATIONAL STUDY

EUGENIA IRENE DAVIDESCU1,2*, IRINA ODAJIU1, MIRELA DUMITRIŢĂ ILIE1, TEODORA BUNEA1, GEORGIANA SANDU1, LAURENŢIU STRATAN2,4, NICOLETA IFTODE4, VICTORIA ARAMĂ2,4, BOGDAN OVIDIU POPESCU1,2,3

1Neurology Department, Colentina Clinical Hospital, Bucharest, Romania
2“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3Laboratory of Cell Biology, Neurosciences and Experimental Myology, “Victor Babeş” National Institute of Pathology, Bucharest, Romania
4“Matei Balș” National Institute of Infectious Diseases, Bucharest, Romania

*corresponding author: eugenia.davidescu@umfcd.ro

Manuscript received: August 2020

Abstract

Cytokine storm seems to be one of the main culprits for developing a severe form of COVID-19. IL-6 being one of its basic components. Therefore, currently, tocilizumab is widely studied as a powerful treatment in patients with severe forms of COVID-19. Our aim was to determine whether it could potentiate a favourable outcome in such patients. We conducted a retrospective observational study including all consecutive admitted patients with confirmed SARS-CoV-2 infection that received treatment with tocilizumab in the period between 01.05-23.08.2020 in “Matei Balș” National Institute for Infectious Diseases and Neurology Department of the Colentina Clinical Hospital in Bucharest, Romania. 22 patients were enrolled with a severe form of COVID-19, predominantly women, with an average age of 61.72 ± 14.5 years. The fatality rate was 31.81%. It was observed that following tocilizumab administration, patients presented improvement in the majority of the studied parameters, statistically significant in the case of fibrinogen, C reactive protein and blood oxygen level (p < 0.05). Tocilizumab might be regarded as a valuable drug in the management of severe SARS-CoV-2 infection.

Rezumat

Furtuna de citokine pare a fi una dintre principalele cauze pentru dezvoltarea unei forme severe de COVID-19. IL-6 fiind una dintre componentele sale de bază. Prin urmare, tocilizumab este studiat pe scară largă ca un tratament la pacienții cu forme severe de COVID-19. Scopul studiului a fost de a determina dacă ar putea potenția un rezultat favorabil al astfel de pacienți. S-a realizat un studiu observațional retrospectiv care a inclus toți pacienții internați cu infecție confirmată de SARS-CoV-2 care au primit tratament cu tocilizumab în perioada 01.05-23.08.2020 în cadrul Institutului Național pentru Boli Infecțioase „Matei Balș” și al Departamentului de Neurologie al Spitalului Clinic Colentina din București, România. 22 de pacienți au fost înrolați cu o formă severă de COVID-19, predominant femei, cu o vârstă medie de 61.72 ± 14.5 ani. Rata mortalității a fost de 31.81%. S-a observat că, după administrarea tocilizumab, pacienții au prezentat îmbunătățiri în majoritatea parametrilor studiați, semnificativ statistic în cazul fibrinogenului, al concentrației proteinei C reactive și al nivelului de oxigen din sânge (p < 0.05). Tocilizumab ar putea fi considerat un medicament valoros în gestionarea infecției severe cu SARS-CoV-2.

Keywords: COVID-19, severe form, tocilizumab

Introduction

The emergence of the “2019 novel coronavirus” or “2019-nCoV”, later renamed by the World Health Organization as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent of “Coronavirus Disease 2019” (COVID-19), has profoundly changed our lives [29]. In only 8 months since its emergence in the Hubei province of China, SARS-CoV-2 managed to spread all over the world infected over 24 million people and killed more than 830,000 subjects [30]. As reported by the clinical data from Wuhan, China, around 17.7 - 32.0% of the patients required admission to Intensive Care Unit (ICU) and approximately 9.5 - 12.0 days after the first symptoms, some developed multi-organ failure. Therefore, the mortality in patients with severe to critical COVID-19 disease can be as high as 49.0 - 61.5% [27, 29].

Regardless of its name, SARS-CoV-2 infection should be considered a multisystem disease. This is mostly related to the fact that the virus enters the cells by binding with its S1 C-terminal domain of the spike protein to the angiotensin-converting enzyme 2 receptor [30], which is widely spread through the human body – lung, stomach, small intestine, colon, skin, lymph nodes, thymus, spleen, liver, kidney, brain, endothelial cells
Subjects
In this retrospective observational study were included all patients with confirmed infection with SARS-CoV-2 that received treatment with tocilizumab, apart from standard therapy in the period between 01.05.2020 and 23.08.2020, consecutively admitted to “Matei Balș” National Institute for Infectious Diseases or to Neurology Department of the Colentina Clinical Hospital in Bucharest, Romania. Informed consent was obtained from the patients or from a legal representative over the telephone, due to biosafety reasons. The patients were managed according to the internal and the national treatment guidelines corresponding to the aforementioned period, which were timely, updated (www.cnscbt.ro). The study was performed in compliance with the World Medical Association Declaration of Helsinki from 1975.

The recommendation to administer tocilizumab was issued by the infectious disease specialist, in accordance with the patients’ condition, in accordance to the national and international treatment guidelines for COVID-19 [4 - 8 mg/kg bw, 1 to 3 doses, at least 8 to 12 hours apart]. Severe forms were considered in patients with evidence of bilateral interstitial pneumonia, low SaO₂ (blood oxygen level) requiring supplemental oxygen delivery +/- presence of dyspnoea, progressive inflammatory syndrome as well as increased D-dimer concentrations.

The standard treatment included non-invasive mechanical ventilation: nasal cannula, facial mask or high-flow ventilation according to patients’ respiratory requirements, low-molecular-weight heparin in prophylactic or even therapeutic dosage, dexamethasone and a combination of at least two antibiotics (ceftriaxone, linezolid, meropenem, amoxicillin/clavulanic acid, colistin, vancomycin, azithromycin, doxycycline) depending on the patient’s clinical and paraclinical parameters. Some patients also received hydroxychloroquine, azithromycin or umifenovir.

Data analysis
Data was collected from the patients’ medical records after discharge. It was analysed using Microsoft Excel. Data analysis and t-test for two-samples assuming equal variances. Initial hypothesis was that the duration of symptoms could be negatively correlated with the outcome. We analysed the influence of tocilizumab’s administration on patients’ clinical and paraclinical evolution. We followed the corresponding values of leucocytes, lymphocytes, neutrophils, C reactive protein (CRP), fibrinogen, procalcitonin, ferritin, IL-6, D-dimers, aspartate transaminase (AST), alanine transaminase (ALT), creatinine and SaO₂ – measured with a finger pulse oximeter. Blood was drawn using venipuncture in clot activator vacutainer tubes for serum separation, then it was processed in a COBAS 8000 Analyzer or in a VITROS 5.1 FS for biochemistry and in a SYSMEX XN 3000 Analyzer or in a DxH 900 High Volume Lab Hematology Analyzer for complete blood count. The extraction of SARS-CoV-2 was performed using an automatic extractor and certified and validated CE-IVD Real Time PCR (polymerase chain reaction) Kits with the CFX 96 Analyzer (GRAL, Medical Molecular Biology Laboratory, Bucharest, Romania), respecting the workflow and all necessary conditions with BSL-2 safety level.
For lacking data, we used the mean values for that parameter. We also performed a synthetization of the available articles on Pubmed using the “tocilizumab and Covid-19” as searching elements and included the available published or preprint versions of the studies performed since the start of the pandemic.

**Results and Discussion**

22 patients with severe COVID-19 were included, with a slightly higher preponderance for women – 12 (54.54%) and an average age of 61.72 ± 14.5 (range: 30 - 88) years. There was a single patient without comorbidities and 5 out of the other 21 did not follow any treatment at home. The type of encountered concomitant pathologies along with their proportion is presented in Table I.

**Table I**

| Patients comorbidities                                      | Number of patients (%) |
|------------------------------------------------------------|------------------------|
| Hypertension                                               | 16 (72.72%)            |
| Cardiovascular disease                                     | 11 (50%)               |
| Obesity                                                    | 9 (40.9%)              |
| Diabetes mellitus                                          | 7 (31.81%)             |
| Dyslipidaemia                                              | 5 (22.72%)             |
| Oncological pathology (colon cancer, basocellular carcinoma, prostate adenocarcinoma) | 5 (22.72%)             |
| Neurological disease (Parkinson disease, myasthenia gravis, chronic diabetic polynueopathy) | 4 (18.18%)             |
| Inflammatory disease                                       |                        |
| Previous smokers                                           | 3 (13.63%)             |
| Chronic kidney disease                                     | 2 (9.09%)              |
| Thrombophilia                                              |                        |
| Polinodular goiter                                         |                        |
| Hypersensibility reaction                                  | 1 (4.05%)              |
| Active smoking                                             |                        |

With reference to patients’ symptomatology on hospital admission, the percentages are presented in Figure 1. Regarding concomitant neurological symptoms, it is important to mention that 5 patients (22.72%) had motor deficit, which was later confirmed to be due to ischemic stroke, 2 patients presented confusion and one patient - an episode of loss of consciousness.

**Figure 1.**

*Patients’ symptomatology on admission*

Out of the 22 patients enrolled, 7 died during their hospital stay (31.81%). Speaking about the subjects’ biological tests on admission, we have to mention that the majority had lymphopenia, inflammatory syndrome and elevated D-dimers. The average values of these paraclinical parameters are presented in Table II.
It has to be outlined that the values for IL-6 were not included in the final analysis, as it was tested in less than half of the patients before and after tocilizumab’s administration, we could only mention that it was significantly elevated in 64.28% of the tested patients with a mean value of 155.48 ± 244.53 pg/mL and following treatment it dropped to an average of 112.015 ± 257.29 pg/mL. Regarding procalcitonin, it was tested in only 68.18% initially with a mean value of 21.05 ± 9.01 ng/mL and following treatment with a mean value of 23.64 ± 11.61 ng/mL. It is also important to mention that all patients required supplemental oxygen delivery from the very start as follows: 3 subjects received oxygen through nasal canula (4 L/min), 11 patients through facial mask (8 - 16 L/min) and 8 required high flow delivery (18 - 30 L/min), out of which 2 patients were later mechanically ventilated for up to 8 days.

As regards pulmonary imaging, there were identified signs of severe bilateral interstitial pneumonia (involving > 50% of pulmonary parenchyma) in 10 patients (45.45%), moderate in 6 subjects (27.27%) (involving between 25 - 50%) and mild also in 6 patients (27.27%) (involving < 25% of pulmonary parenchyma). The mean duration of hospital stay was 18.54 ± 9.79 (range: 3 - 40) days, less for the deceased patients, on average 11.14 ± 13.03 days (except one patient – 40 days), comparative to those who had a favourable evolution – 21.46 ± 6.51 days. In regard to the patients’ evolution following treatment, it is important to outline that there was an improvement in all studied parameters, the most important ones being observed in the case of fibrinogen, CRP as well and in blood oxygen levels that were statistically significant (p < 0.05), for the patients that had a favourable evolution (data presented in Table III).

### Table II

| Parameter         | Patients with favourable evolution (15) (% - mean value) | Deceased patients (7) (% - mean value) |
|-------------------|----------------------------------------------------------|----------------------------------------|
| Leukocytosis      | 80% (1037.5 x 1000/mL)                                   | 57.14% (16885 x 1000/mL)               |
| Lymphopenia       | 26.66% (8465 x 1000/mL)                                  | 100% (914.28 x 1000/mL)                |
| Neutrophilia      |                                                          | 57.14% (15220 x 1000/mL)               |
| Ferritin ↑        | 46.66% (831.46 mg/mL)                                    | 85.71% (1202.14 mg/mL)                 |
| Fibrinogen ↑      | 53.33% (644.12 mg/dL)                                    | 71.42% (538.6 mg/dL)                   |
| CRP ↑             | 93.33% (49.95 mg/L)                                      | 85.71% (111.32mg/L)                    |
| D-dimers ↑        | 18.18% (1247.5 mg/mL)                                    | 85.71% (8095 ng/mL)                    |
| AST↑              | 60% (57.88 Ul/mL)                                        | 28.57% (44.8 Ul/mL)                    |
| ALT↑              | 33.33% (83.82 Ul/L)                                      | 0                                      |
| Creatinine (mean) | 1.17 mg/dL                                               | 1.11 mg/dL                             |
| SaO₂↓             | 60% (84.5%)                                              | 71.42% (85%)                           |

CRP = C reactive protein; AST = aspartate transaminase; ALT = alanine transaminase; SaO₂ – blood oxygen level

The extent of time from the appearance of initial symptoms until treatment initiation did not positively influence the outcome, being even larger for patients with a favourable evolution with a mean number of days of 9.46 ± 3.66 versus the deceased ones – 6 ± 1.29 (p < 0.02). In regard to the total administered dose of tocilizumab, the average values were almost the same – 1949.33 ± 483.66 mg for patients with a favourable outcome and 1985.71 ± 758.13 mg for the other ones. Factors that had a more significant influence on the outcome were age, patients with a poor evolution being significantly older 73.85 ± 8.97 years, in comparison to those with a favourable outcome – 56.06 ± 13.02 years (p < 0.002) and comorbidity: all patients with a poor outcome were hypertensive, 57% of them were obese and had cardiovascular pathology versus 33.33% of those with a positive evolution. It is also important to highlight that all presented with severe bilateral pneumonia, low blood oxygen levels, moderate to severe lymphopenia, significant systemic inflammation and a higher concentration of D-dimers since admission.

Concerning the adverse events related to tocilizumab therapy, a significant increase in the values of the ALT (p < 0.02) as well as AST (p < 0.007) was observed. The extent of time from the administration of tocilizumab to the peak of the adverse event median was 15.14 days.

### Table III

| Parameter         | Patients with favourable outcome (p < 0.001) | Deceased patients |
|-------------------|---------------------------------------------|-------------------|
| Fibrinogen ↓      | 1.86 x initial mean value (IMV)              | 1.43 x IMV (p < 0.03) |
| CRP ↑             | 4.66 x IMV (p < 0.02)                        | 1.55 x IMV (p < 0.23) |
| Ferritin ↑        | 1.26 x IMV (p < 0.02)                        | 1.09 x IMV (p < 0.38) |
| SaO₂↓             | 1.07 x IMV (p < 0.005)                       | 1.07 x IMV (p < 0.16) |
| D-dimers↓         | 1.34 x IMV (p < 0.025)                       | 1.49 x IMV (p < 0.27) |
| Lymphocytes ↑     | 1.46 x IMV (p < 0.18)                        | 1.06 x IMV (p < 0.4)  |
| Leucocytes ↓      | 1.3 x IMV (p < 0.14)                         | 1.07 x IMV (p < 0.4)  |

CRP = C reactive protein; SaO₂ – blood oxygen level
observed, apparently not correlated with the total administered dose \((r = 0.04, p < 0.59)\). The obtained results of this retrospective observational analysis point to a positive influence of tocilizumab on the outcome of patients with severe COVID-19, the fatality rate being 31.81%. It is necessary to remark that the potential factors influencing the outcome were older age, a greater incidence of comorbidity along with a worse clinical status and a more severe inflammatory syndrome at onset. Our results indicate that tocilizumab therapy could significantly reduce inflammatory markers such as CRP and fibrinogen as well as improve \(\text{SaO}_2\), reducing the need of supplemental oxygen delivery \((p < 0.05)\). The majority of patients presented bacterial co-infection and super-infection, evaluated using procalcitonin levels and cultures at admission and following tocilizumab usage that demanded antibiotic treatment which could also influence the outcome. 

The hypothesis that an earlier administration of tocilizumab could prevent a negative outcome was not supported by our results \((p < 0.02)\), a potential explanation being the small number of included patients, reduced homogeneity among subjects and lack of a control group. Among other biases that could have influenced the results could be mentioned the fact that the patients were from two different institutions, and even if the management was based on the same protocol, the characteristics of the patients, namely age, comorbidities, presentation – were different. With reference to the potential adverse events, namely elevation of liver enzymes, it cannot be excluded that it could be also related to the administration of other concomitant drugs such as combination antibiotic therapy, hydroxychloroquine and dexamethasone. Our results were in line with the observations made by other studies conducted in this period, presented in Table IV, except for 2 studies according to which there seems to be no positive influence on the patients’ outcome \([5, 9]\).

We await the results of larger randomized-control trials in order to fully perceive the efficiency and safety of tocilizumab in COVID-19 patients, that would also respond to the question regarding the proper moment of administration, since an early delivery of tocilizumab might impair the thymocyte differentiation into cytotoxic T cells as well as IgM and IgG production by B cells which is promoted by IL-6 and thus could encourage viral replication \([28]\). On the other hand, a late tocilizumab administration might be totally ineffective \([22]\).

**Table IV**

| Article | Type of study | Number of patients | Other treatments | Outcome |
|---------|--------------|--------------------|-----------------|---------|
| [26] J Med Virol., 2020 Jul; 92(7): 814-818. | Observational retrospective study (China) | 21 | Lack of data | Improvement of respiratory function, normalization of lymphocyte count, reduction in CRP values and lung opacities in 90.5% |
| [15] | Retrospective observational study (China) | 15 | Methylprednisolone | 4 out 7 patients aggravated or died regardless of a decrease in CRP values; |
| [1] J Med Virol., 2020 May 5 | Retrospective study (Qatar) | 25 | Lopinavir/ritonavir, ribavirin and/or interferon alpha 2-a, hydroxychloroquine, azithromycin | Amelioration of the respiratory function, reduction of the level of inflammatory markers, radiological improvement |
| [7] Eur J Intern Med., 2020 Jun; 76: 31–35 | Preliminary results of a non-randomized prospective study (Italy) | 25 | Hydroxychloroquine, lopinavir/ritonavir | % of patients treated with tocilizumab who completely recovered and had a more positive clinical course, was higher compared to those who underwent only standard therapy (92% to 42.1% respectively) |
| [25] Autoimmun Rev., 2020 Jul; 19(7): 102568 | Prospective multicentre study (Italy) | 100 | Lopinavir/ritonavir or remdesivir, antibiotics (azithromycin, ceftriaxone or piperacillin/tazobactam), hydroxychloroquine and dexamethasone | A rapid sustained response at 24 - 72 h following drug administration in around 70% of the patients and at 10 days, a substantial clearance of pulmonary lesions on chest X-ray |
| [9] Microorganisms, 2020 May 9; 8(5): 695 | Preliminary results from the SMAtteto COVID19 Registry (SMACORE) (Italy) | 21 | Hydroxychloroquine, azithromycin, low weight heparin – prophylactic dose | Tocilizumab administration did not reduce ICU admission or mortality rate |
| Article | Type of study | Number of patients | Other treatments | Outcome |
|---------|--------------|--------------------|-----------------|---------|
| *Eur J Intern Med.*, 2020 Jun; 76: 43–49 | Single-centre retrospective cohort study (Italy) | 32 | Hydroxychloroquine, lopinavir/ritonavir, | No statistical difference regarding clinical amelioration and mortality at day 28 |
| [16] | Multi-centre cohort study (Spain) | 260 | Corticosteroids, hydroxychloroquine, azithromycin, lopinavir/ritonavir | 66% reduction of mortality risk in subjects with baseline CRP levels > 150 mg/L who received tocilizumab |
| [17] | Observational single-centre study (Italy) | 130 | Hydroxychloroquine, darunavir/ritonavir, +/- methylprednisolone | Patients with tocilizumab +/- methylprednisolone had a higher failure-free survival 80.8% versus those without 64.1% and higher overall survival 85.9% vs. 71.9% |
| [20] | Multi-centre single-arm, hypothesis-driven phase 2 trial (Italy) | 180 | Antiviral treatment, corticosteroids | Reduced lethality rate at 30 days with no significant toxicity |
| [24] | Single-centre cohort study (USA) | 78 | Hydroxychloroquine initially, later it was removed from protocol and remdesivir given +/- corticosteroids | Treatment was associated with a decreased fatality likelihood, but an increased rate of superinfection |
| [10] | Retrospective observational cohort study (Italy) | 179 | Hydroxychloroquine, azithromycin, lopinavir/ritonavir or darunavir-cobicistat | Reduced risk of invasive mechanical ventilation or death |

Conclusions

Given that there is no standard gold therapy for SARS-CoV-2 infection, tocilizumab might be regarded as a valuable drug for the patients with this new disease, positively influencing the outcome, especially by reducing the inflammatory syndrome and improving blood oxygen level.

Conflict of interest

The authors declare no conflict of interest.

References

1. Alattar R, Ibrahim TBH, Shaar SH, Abdalla S, Shukri K, Daghfal JN, Khatib MY, Aboukamar M, Abukhattab M, Alsoub HA, Almaslamani MA, Omrani AS, Tocilizumab for the treatment of severe coronavirus disease 2019. *J Med Virol.*, 2020; 1-8.
2. Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Efficiency of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. *Neurology*, 2014; 82(15): 1302-1306.
3. Aziz M, Fatima R, Assaly R, Elevated interleukin-6 and severe COVID-19: A meta-analysis. *J Med Virol.*, 2020; 92(11): 2283-2285.
4. Blejan IE, Diaconsu CC, Arseni AL, Udeanu DI, Ghica M, Drăganescu D, Burea Dragomiroiu GTA, Rădulescu M, Maltezu HC, Tatsakis AM, Papasavva M, Drahoulis N, Popa DE, Antibiotic resistance in community-acquired pneumonia. A Romanian perspective. *Farmacia*, 2020; 68(3): 512-520.
5. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, Tomelleri A, Baldissera E, Rovere-Querini P, Ruggeri A, Monti G, De Cobelli F, Zangrillo A, Tresoldi M, Castagna A, Dagna L, Group TRS, Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. *Eur J Intern Med.*, 2020; 76: 43-49.
6. Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D, Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. *Mediators Inflamm.*, 2017; 2017; Art. ID 8909834: 1-15.
7. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, Cossi S, Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med.*, 2020; 76: 31-35.
8. Chen T, Wu D, Chen H, Yuan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ*, 2020; 368: m1091: 1-25.
9. Colaneri M, Boglioni L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, Montecucco C, Mojoli F, Giusti EM, Bruno R, The Covid Irccs San Matteo Pavia Task Force, Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAatte
Covid19 REGistry (SMACORE). Microorganisms, 2020; 8(5): 695: 1-12.

10. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A, Di Gaetano M, Puzzolante C, Carlì F, Bedini A, Corradi L, Fantini R, Castaniere I, Tabbi L, Girardis M, Tedeschi S, Giannaelli M, Bartoletti M, Pascale R, Dolci G, Brugioni L, Pietrangelo A, Cossarizza A, Pea F, Cini E, Salvadori C, Massari M, Viale PL, Mussini C, Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol., 2020; 2(8): e474-e484.

11. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol., 2004; 203(2): 631-637.

12. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xie J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England), 2020; 395(10223): 497-506.

13. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami A, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterol., 2004; 126(4): 989-996.

14. Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, Przepiorka D, Farrell AT, Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist, 2018; 23(8): 943-947.

15. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J, Tocilizumab treatment in COVID-19: A single center experience. J Med Virol., 2020; 92(7): 814-818.

16. Martinez-Sanz J, Muniel A, Ron R, Herrera S, Ron R, Perez-Molina JA, Moreno S, Serrano-Villar S, Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study. Clin Microbiol Infect., 2020; (23): 1-19.

17. Mikulska M, Nicollini LA, Signori A, Di Giacchio A, Sepulcri C, Russo C, Dettori S, Berrutti M, Sormani MP, Giacobbe DR, Vena A, De Maria A, Dentone C, Taramasso L, Mirabella M, Magnusco L, Mora S, Delfino E, Toscanini F, Balletto E, Alessandri AL, Baldi F, Brianza F, Camera M, Dodi F, Ferrazia A, Labate L, Mazzarello G, Pincino R, Portunato F, Tutino S, Barisone E, Bruzzone B, Orsi A, Schenone E, Rossetti N, Sasso E, Da Pelosi P, Beltramini S, Tutino S, Barisione E, Bruzzone B, Orsi A, Schenone L, Mussini G, Tocilizumab and steroid treatment in patients with severe COVID-19 pneumonia. PLoS One, 2020; 15(8): e0237831: 1-16.

18. Moore JB, June CH, Cytokine release syndrome in severe COVID-19. Science, 2020; 368(6490): 473-474.

19. Nanshan Chen, Min Zhou, Xuan Dong, Jiemei Qu, Fengyun Gong, Yang Han, Yang Qiu, Jingli Wang, Ying Lin, Yuan Wei, Jia’an Xia, Ting Yu, Xinxin Zhang. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, 395(10223): 507-513.

20. Perrone F, Piccirillo MC, Ascierzo PA, Salvarani C, Parrella R, Marata AM, Popoli F, Ferraris L, Marrocco Trischitta MM, Ripamonti D, Bindu F, Bonfanti P, Squillace N, Castelli F, Mueslan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Massimo C, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial. Contemp Clin Trials, Elsevier, ahead of print, 2020; 1-24.

21. Oldfield V, Bhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs, 2009; 69(5): 609-632.

22. Radbel J, Narayanan N, Bhatt PJ. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report. Chest, 2020; 158(1): e15-e19.

23. Schiff MH, Kremer JM, Jahres A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther., 2011; 13(5): R141-1: 1.

24. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO, Frame D, Gregg KS, Kaul DR, Nagel J, Patel TS, Zhou S, Lauring AS, Hanauer DA, Martin E, Sharma P, Fung CM, Pogue JM. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis., 2020; 11: 1-24.

25. Toniati P, Piva S, Cantallini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzi C, Beindorf EA, Berlendis M, Betti M, Bossini N, Castellano M, Cattaneo S, Cavazzana I, Contessi GB, Crippa M, Delbarba A, De Peri E, Falleti A, Filippini M, Filippini M, Frassi M, Gaggiotti M, Gorla R, Lanspa M, Marino R, Maroldi R, Metra M, Mattei A, Modina D, Molioli G, Montani G, Mueslan ML, Odolini S, Pei E, Pesenti S, Pezzoli MC, Pirolo I, Pozzi A, Proto A, Rasulo FA, Renisi G, Ricci C, Rizzoni D, Romanelli G, Rossi M, Salvetti M, Scolari F, Signorini L, Taglietti M, Tomasoni G, Tomasoni LR, Turla F, Valsecchi A, Zani D, Zuccalà F, Zanica F, Foci E, Andreoli L, Latronico N. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev., 2020; 19(7): 102568: 1-7.

26. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Li Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA, 2020; 117(20): 10970-10975.

27. Xiaobo Yang, Yuan Yu, Jiqian Xu, Huaqing Shu, Jia’an Xia, Hong Liu, Yongwan Wu, Lu Zhang, Zhui Yu, Minghao Fang, Ting Yu, Yaxin Wang, Wangwen Pan, Xiaojing Zou, Shiyong Yuan, You Shang. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single centered, retrospective, observational study. Lancet Respir Med (London, England), 2020, 8(5): 475-481.
28. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. *Int J Antimicrob Agents*, 2020; 55(5): 105954: 1-7.

29. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. *Zhonghua Liu Xing Bing Xue Za Zhi*, 2020; 41(2): 145-151, (available in Chinese).

30. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature*, 2020; 579(7798): 270-273.

31. ***WHO***, www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.

32. ***University, J. H., Coronavirus Resource Center, 2020,*** https://coronavirus.jhu.edu/map.html.

33. ***www.ema.europa.eu/en/documents/product-information/roactemra***.